CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
National Institutes of Health · Center for Cancer Research · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,336
total citations
- FWCI
- 57.01
- Percentile
- 100%
- References
- 61
Citations per year
Authors
24- TJTerry J. FryCorresponding
National Institutes of Health, Center for Cancer Research
- NNNirali N. Shah
National Institutes of Health, Center for Cancer Research
- RJRimas J. Orentas
National Institutes of Health, Center for Cancer Research
- MSMaryalice Stetler‐Stevenson
Center for Cancer Research
- CMConstance M. Yuan
Center for Cancer Research
Topics & keywords
Topics
Keywords
- CD22
- CD19
- Immunotherapy
- Medicine
- Antigen
- Chimeric antigen receptor
- Immunology
- B cell
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.